London, 11 March 2021 – On 26 January 2021, Hikma Pharmaceuticals PLC (Hikma) announced that it had entered into a non-binding term sheet with GlaxoSmithKline PLC (GSK) for the purposes of potentially acquiring GSK’s pharmaceutical and consumer businesses in Egypt and its pharmaceutical business in Tunisia (the Proposed Transaction).
11 March 2021
Press Release
Hikma today confirms that both companies have agreed to cease discussions regarding the Proposed Transaction and, accordingly, Hikma will not be launching a Mandatory Tender Offer process to acquire the shares in GlaxoSmithKline SAE Egypt.